Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

iShares U.S. Pharmaceutical ETF (NY:IHE)

95.94 +0.86 (+0.90%)

Official Closing Price Updated: 4:10 PM EDT, Jun 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	440,855
Open	95.34
Bid (Size)	95.80 (200)
Ask (Size)	96.75 (3,100)
Prev. Close	95.08
Today's Range	95.34 - 97.21
52wk Range	64.94 - 95.78
Shares Outstanding	82,000
Dividend Yield	1.18%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors? ↗

June 17, 2026

Compare risk profiles, sector concentration, and income potential as these two healthcare ETFs take different approaches to growth and stability.

Via The Motley Fool

iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns ↗

June 10, 2026

One fund channels profits to breast cancer research, while the other focuses on established drugmakers. See how their strategies shape risk and sector exposure.

Via The Motley Fool

Performance

YTD	+13.0%	+13.0%
1 Month	+5.2%	+5.2%
3 Month	+11.5%	+11.5%
6 Month	+11.3%	+11.3%
1 Year	+45.5%	+45.5%

More News

GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game. ↗

May 27, 2026

Via The Motley Fool

KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show? ↗

January 30, 2026

Via Stocktwits

Why Did NRXP Stock Surge 21% Pre-Market Today? ↗

January 14, 2026

Via Stocktwits

White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report ↗

September 26, 2025

Via Stocktwits

FDA Vaccine Chief Vinay Prasad To Exit Agency In April: Report ↗

March 06, 2026

Via Stocktwits

TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint ↗

March 03, 2026

Via Stocktwits

FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development ↗

February 18, 2026

Via Stocktwits

Why Did IINN Stock Surge 28% In Pre-Market Today? ↗

February 09, 2026

Via Stocktwits

HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗

February 05, 2026

Via Stocktwits

LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗

February 04, 2026

Via Stocktwits

US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗

December 01, 2025

Via Stocktwits

Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs ↗

November 15, 2025

Via Benzinga

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗

November 12, 2025

Via Benzinga

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗

October 30, 2025

Via Benzinga

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

Via Benzinga

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗

September 29, 2025

Via Benzinga

Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗

September 08, 2025

Via Benzinga

Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗

August 01, 2025

Via Benzinga

Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption' ↗

July 28, 2025

Via Benzinga

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗

July 26, 2025

Via Benzinga

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Via Benzinga

FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report ↗

July 11, 2025

Via Stocktwits

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Via Benzinga

Frequently Asked Questions

Is iShares U.S. Pharmaceutical ETF publicly traded?

Yes, iShares U.S. Pharmaceutical ETF is publicly traded.

What exchange does iShares U.S. Pharmaceutical ETF trade on?

iShares U.S. Pharmaceutical ETF trades on the New York Stock Exchange

What is the ticker symbol for iShares U.S. Pharmaceutical ETF?

The ticker symbol for iShares U.S. Pharmaceutical ETF is IHE on the New York Stock Exchange

What is the current price of iShares U.S. Pharmaceutical ETF?

The current price of iShares U.S. Pharmaceutical ETF is 95.94

When was iShares U.S. Pharmaceutical ETF last traded?

The last trade of iShares U.S. Pharmaceutical ETF was at 06/25/26 04:10 PM ET

What is the market capitalization of iShares U.S. Pharmaceutical ETF?

The market capitalization of iShares U.S. Pharmaceutical ETF is 7.87M

How many shares of iShares U.S. Pharmaceutical ETF are outstanding?

iShares U.S. Pharmaceutical ETF has 8M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.